Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data
Denali Therapeutics has received FDA Accelerated Approval for its drug AVLAYAH, aimed at treating Hunter syndrome. The company is maintaining a 'Strong Buy' rating due to this approval and the positive momentum of its pipeline. Additionally, the upcoming phase 1/2 data readout for DNL593, targeting FTD-GRN, is anticipated to further bolster investor confidence.
- ▪Denali Therapeutics has been granted FDA Accelerated Approval for AVLAYAH.
- ▪The approval is specifically for the treatment of Hunter syndrome.
- ▪The company is maintaining a 'Strong Buy' rating based on this development and its pipeline progress.
- ▪DNL593, aimed at FTD-GRN, is expected to provide promising data in an upcoming phase 1/2 readout.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4909115-denali-therapeutics-strong-buy-on-avlayah-approval-and-end-of-2026-ftd-grn-data"},"author":{"@type":"Person","name":"Terry…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
